JNNP podcast show

JNNP podcast

Summary: From June 2023, all our podcasts will move to https://jnnpbmj.podbean.com. You can continue with your subscription on your favourite podcast App. JNNP's ambition is to publish the most ground-breaking and cutting-edge research from around the world. Encompassing the entire genre of neurological sciences, our focus is on the common disorders (stroke, multiple sclerosis, Parkinson's disease, epilepsy, peripheral neuropathy, subarachnoid haemorrhage and neuropsychiatry), but with a keen interest in the Gordian knots that present themselves in the field, such as ALS. * The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.

Podcasts:

 Do genes affect age of onset in ALS? | File Type: audio/mpeg | Duration: 9:50

Professor Ammar Al-Chalabi (King’s College London, London, UK) joins Elizabeth Highton (podcast editor) to discuss motor neurone disease, also known as amyotrophic lateral sclerosis or ALS, a rapidly progressive illness resulting from the degeneration of both upper and lower motor neurons. Studies have shown that age of onset is younger in people with a family history – but it this due to a heightened knowledge of the disease or due to genetics lowering the age of onset? Read the full paper here: https://jnnp.bmj.com/content/jnnp/90/3/268.

 The lifetime risk of common neurological disorders in the elderly population | File Type: audio/mpeg | Duration: 6:17

We have a good understanding of our risk of developing cancer or heart disease – but what do we know about the risk of developing a common neurological disorder in later-life? Dr. Silvan Licher (Department of Epidemiology, University Medical Center Rotterdam, Netherlands) discusses the lifetime risk of developing dementia, stroke, and Parkinson’s disease, and how we need to better prioritise preventive interventions. Read the full paper here: https://jnnp.bmj.com/content/jnnp/90/2/148.full.pdf

 The lifetime risk of common neurological disorders in the elderly population | File Type: audio/mpeg | Duration: 6:17

We have a good understanding of our risk of developing cancer or heart disease – but what do we know about the risk of developing a common neurological disorder in later-life? Dr. Silvan Licher (Department of Epidemiology, University Medical Center Rotterdam, Netherlands) discusses the lifetime risk of developing dementia, stroke, and Parkinson’s disease, and how we need to better prioritise preventive interventions. Read the full paper here: https://jnnp.bmj.com/content/jnnp/90/2/148.full.pdf

 PMA and PLS: are they really restricted phenotypes? | File Type: audio/mpeg | Duration: 8:57

Dr. Michael van Es (University Medical Center Utrecht, Netherlands) examines whether cognitive and behavioural changes can be seen across the motor neurone disease spectrum, and how this helps inform our understanding of these as multidimensional diseases. Read the editorial commentary by Professor Martin Turner here: https://jnnp.bmj.com/content/90/2/122

 PMA and PLS: are they really restricted phenotypes? | File Type: audio/mpeg | Duration: 8:57

Dr. Michael van Es (University Medical Center Utrecht, Netherlands) examines whether cognitive and behavioural changes can be seen across the motor neurone disease spectrum, and how this helps inform our understanding of these as multidimensional diseases. Read the editorial commentary by Professor Martin Turner here: https://jnnp.bmj.com/content/90/2/122

 Statins and the risk of recurrent intracerebral haemorrhage (ICH) – what does the evidence say? | File Type: audio/mpeg | Duration: 12:02

Do statins increase the risk of intracerebral haemorrhage (ICH) in patients with a previous stroke? Professor David Werring (Stroke Research Centre, UCL Institute Of Neurology, Queen Square, London, UK) joins Elizabeth Highton (JNNP podcast editor) for the first JNNP podcast of 2019. Read the full paper here: https://jnnp.bmj.com/content/90/1/75

 Statins and the risk of recurrent intracerebral haemorrhage (ICH) – what does the evidence say? | File Type: audio/mpeg | Duration: 12:02

Do statins increase the risk of intracerebral haemorrhage (ICH) in patients with a previous stroke? Professor David Werring (Stroke Research Centre, UCL Institute Of Neurology, Queen Square, London, UK) joins Elizabeth Highton (JNNP podcast editor) for the first JNNP podcast of 2019. Read the full paper here: https://jnnp.bmj.com/content/90/1/75

 Functional impairment and improvement | File Type: audio/mpeg | Duration: 28:56

Elizabeth Highton (podcast editor) hosts the final JNNP podcast for 2018, an episode on functional improvement after stroke (Dr. Aravind Ganesh, University of Oxford, UK- https://jnnp.bmj.com/content/89/12/1301) and cognitive impairment in functional neurological disorders (Dr. Jeremy Isaacs (St George’s University and Hospital, London, UK - https://jnnp.bmj.com/content/89/12/1308).

 Functional impairment and improvement | File Type: audio/mpeg | Duration: 28:56

Elizabeth Highton (podcast editor) hosts the final JNNP podcast for 2018, an episode on functional improvement after stroke (Dr. Aravind Ganesh, University of Oxford, UK- https://jnnp.bmj.com/content/89/12/1301) and cognitive impairment in functional neurological disorders (Dr. Jeremy Isaacs (St George’s University and Hospital, London, UK - https://jnnp.bmj.com/content/89/12/1308).

 Can computational models help us understand complex movement disorders? | File Type: audio/mpeg | Duration: 11:52

Professor Mark Humphries (University of Nottingham, UK) discusses how computational modelling could be a crucial tool in untangling the complexities of diseases like Parkinson’s disease. Can this type of modelling help us understand causes, and eventually lead to treatment options? Read the full paper here: https://jnnp.bmj.com/content/early/2018/04/17/jnnp-2017-315922.long

 Can computational models help us understand complex movement disorders? | File Type: audio/mpeg | Duration: 11:52

Professor Mark Humphries (University of Nottingham, UK) discusses how computational modelling could be a crucial tool in untangling the complexities of diseases like Parkinson’s disease. Can this type of modelling help us understand causes, and eventually lead to treatment options? Read the full paper here: https://jnnp.bmj.com/content/early/2018/04/17/jnnp-2017-315922.long

 Idiopathic intracranial hypertension: guidelines for diagnosis and management | File Type: audio/mpeg | Duration: 14:55

In collaboration with many different specialists, professions and patient representatives, Mollan et al (2018) have developed the first ever guidelines for the investigation and management of idiopathic intracranial hypertension (IIH). Senior author, Dr Alexandra Sinclair (University of Birmingham) discusses these with the JNNP podcast editor, Elizabeth Highton. Read the full guidelines here: https://jnnp.bmj.com/content/89/10/1088 Access the Practical Neurology infographic summary here: https://pn.bmj.com/content/early/2018/08/28/practneurol-2018-002009

 Idiopathic intracranial hypertension: guidelines for diagnosis and management | File Type: audio/mpeg | Duration: 14:55

In collaboration with many different specialists, professions and patient representatives, Mollan et al (2018) have developed the first ever guidelines for the investigation and management of idiopathic intracranial hypertension (IIH). Senior author, Dr Alexandra Sinclair (University of Birmingham) discusses these with the JNNP podcast editor, Elizabeth Highton. Read the full guidelines here: https://jnnp.bmj.com/content/89/10/1088 Access the Practical Neurology infographic summary here: https://pn.bmj.com/content/early/2018/08/28/practneurol-2018-002009

 Nusinersen for SMA | File Type: audio/mpeg | Duration: 10:20

Elizabeth Highton (JNNP Podcast Editor) speaks with Dr. Michelle Farrar (University of New South Wales) discussing nusinersen, the first disease-modifying therapy for spinal muscular atrophy type 1 (SMA). https://jnnp.bmj.com/content/89/9/937

 Nusinersen for SMA | File Type: audio/mpeg | Duration: 10:20

Elizabeth Highton (JNNP Podcast Editor) speaks with Dr. Michelle Farrar (University of New South Wales) discussing nusinersen, the first disease-modifying therapy for spinal muscular atrophy type 1 (SMA). https://jnnp.bmj.com/content/89/9/937

Comments

Login or signup comment.